۵.

Interional Application No PCT/DK 03/00794

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12Q1/68 G01M G01N33/50 G01N33/574 G01N33/68 C12N15/12 C12N15/85 C07K14/47 C07K16/18 C12P21/00 A61K31/7088 A61K38/16 A61K39/00 A61K39/395 A61K48/00 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12Q G01N C12N C07K A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, Sequence Search, EMBL C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Α DAMLE R ET AL: "B-cell chronic 1-7 lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes" BLOOD. vol. 99, no. 11, June 2002 (2002-06), pages 4087-93, XP002248139 the whole document Α KRÕBER A ET AL: "VH mutation status, CD38 1-7 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia" BLOOD, vol. 100, no. 4, August 2002 (2002-08), pages 1410-16, XP002248141 cited in the application the whole document Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention *E* earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannol be considered to involve an Inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the ort. "O" document referring to an oral disclosure, use, exhibition or document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 9 August 2004 16/08/2004 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL ~ 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016 Osborne, H

Interioral Application No PCT/DK 03/00794

C (Cardian	-V POOUNTATO CONCERNED TO DE DEL EVANE	PCT/DK 03/00794	
Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
A	LIN K ET AL: "Relationship between p53 dysfunction, CD38 expression, and IgVH mutation in chronic lyphocytic leukemia" BLOOD, vol. 100, no. 4, August 2002 (2002-08), pages 1404-09, XP002248142 cited in the application the whole document	1-7	
A	OSCIER D ET AL: "Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors" BLOOD, vol. 100, no. 4, August 2002 (2002-08), pages 1177-84, XP002248143 cited in the application the whole document	1-7	
A	WO 00/44788 A (HARIHARAN KANDASAMY; LABARRE MICHAEL J (US); HANNA NABIL (US); HUY) 3 August 2000 (2000-08-03) claim 19		
Α	DATABASE EMBL 'Online! Homosapiens 12 BAC RP11-693J15 26 April 2000 (2000-04-26), MUZNY D ET AL: "Homosapiens 12 BAC RP11-693J15" XP002248623 retrieved from EBI Database accession no. AC063949 99.8% identity in overlap of 1959 nt of SEQ ID NO 2 (1935-3893) to nucleotides 56450-58408 of AC063949	8	
A	WO 01/64886 A (CORIXA CORP) 7 September 2001 (2001-09-07)		

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 34 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.


Continuation of Box I.2

Claims Nos.: 16-25

Present claims 16-25 relate to use of and methods for treatment in which both make use of a compound defined by reference to a desirable characteristic or property, namely the compound is capable of eliminating transcription of at least one of the expression products defined in terms of their SEQ ID Nos.

The claims cover all compounds, inter alia ribozymes (see description) and si-RNA (claim 25) having this characteristic or property, whereas the application provides no support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has not been carried out for the above mentioned claims.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.



Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: 16-25 because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 34 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X Claims Nos.: 16-25 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority clid not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

PCT/DK 03/00794

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 0044788	A	03-08-2000	AU CA EP JP WO	3473100 A 2359994 A1 1157042 A1 2002536969 T 0044788 A1	18-08-2000 03-08-2000 28-11-2001 05-11-2002 03-08-2000
₩0 0164886	A	07-09-2001	AU WO US US US US	4347701 A 0164886 A2 2003078396 A1 2004002068 A1 2004005561 A1 2002198362 A1	12-09-2001 07-09-2001 24-04-2003 01-01-2004 08-01-2004 26-12-2002